Drug EfficacyRP1 + Opdivo has demonstrated a strong response rate across various patient sub-groups, indicating consistent effectiveness.
Regulatory MilestonesReplimune's focus on RP1 in anti-PD-1-failed melanoma, along with the expected BLA submission, sets the stage for potential market introduction and revenue generation.
Safety ProfileRP1 + Opdivo showcases a favorable safety profile with minimal high-grade adverse events, highlighting its potential as a well-tolerated treatment option.